JNJ, EC Conclude Exploratory Talks Over Covid-19 Candidate
August 13 2020 - 1:55PM
Dow Jones News
By Stephen Nakrosis
Pharmaceutical company Johnson & Johnson on Thursday said it
concluded exploratory talks with the European Commission which may
lead to its Janssen Pharmaceutica NV providing its Covid-19
candidate to EU member states.
Johnson and Johnson said Janssen Pharmaceutica will now enter
into contract talks with the European Commission, which could lead
to it providing 200 million doses of Janssen's SARS-CoV-2
candidate, Ad26.COV2.S, with the possibility of another 200 million
doses being purchased by the Commission.
"If regulatory approval for the company's vaccine is received,
the Commission would be expected to facilitate a process for
allocation of the vaccine doses among the member states," Johnson
and Johnson said.
Paul Stoffels, the chief scientific officer of Johnson &
Johnson, said, "We are deeply committed to providing global access
to our SARS-CoV-2 vaccine candidate. That's why, as we proceed with
development of our vaccine, we are simultaneously working with
partners around the world including the European Commission and
Member States to help us reach that goal."
Janssen Pharmaceutica NV is one of the Janssen Pharmaceutical
Companies of Johnson & Johnson.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 13, 2020 13:40 ET (17:40 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024